GlassScriptPhysician profile
Seva Papageorge
NPI 1508836206
$8,877.62
in general payments reported to CMS, 2019-2025
57 companies · $1,525 in 2025
The $1,525 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $921 · 2020: $655 · 2021: $1,352 · 2022: $1,397 · 2023: $1,398 · 2024: $1,630 · 2025: $1,525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,552.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,552.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,572.93 | 2019-2025 | |
| Novo Nordisk INC | $1,184.24 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $586.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $503.96 | 2019-2025 | |
| Glaxosmithkline, LLC. | $473.38 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $442.53 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $379.78 | 2019-2025 | Repatha, Evenity, Otezla |
| Biohaven Pharmaceutical Holding Company LTD. | $254.65 | 2022 | |
| Abbott Laboratories | $237.86 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.74 | 2019-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $230.88 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $228.10 | 2019-2022 | |
| Eisai INC. | $222.27 | 2019-2022 | |
| Radius Health, INC. | $186.26 | 2022-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.37 | 2019-2023 | Jardiance |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Seva Papageorge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.